Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  The Lancet

• Publication date

  2005-04-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(05)66374-XPMID 15836887
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice

  2005cited by this paper
• Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary.

  2004cited by this paper
• Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.

  2004cited by this paper
• The endocannabinoid system and its therapeutic exploitation

  2004cited by this paper
• Waist circumference and not body mass index explains obesity-related health risk.

  2004cited by this paper
• The obesity epidemic, metabolic syndrome and future prevention strategies

  2004cited by this paper
• Cannabinoid physiology and pharmacology: 30 years of progress.

  2004cited by this paper
• The endocannabinoid system: a general view and latest additions

  2004cited by this paper
• Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: Group I: worldwide demographics of obesity.

  2004cited by this paper
• Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.

  2003cited by this paper
• Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies.

  2003cited by this paper
• Endogenous cannabinoids: a new target in the treatment of obesity.

  2003cited by this paper
• Endogenous cannabinoid system as a modulator of food intake

  2003cited by this paper
• The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.

  2003cited by this paper
• Endocannabinoids and the regulation of body fat: the smoke is clearing.

  2003cited by this paper
• The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.

  2003cited by this paper
• NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older.

  2003cited by this paper
• Cannabinoid receptors.

  2002cited by this paper
• Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds.

  2002cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding

  2002cited by this paper
• The cannabinoid receptors.

  2002cited by this paper
• The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

  2001cited by this paper
• Endogenous glucose production is inhibited by the adipose-derived protein Acrp30.

  2001cited by this paper
• Novel Physiologic Functions of Endocannabinoids as Revealed Through the Use of Mutant Mice

  2001cited by this paper
• Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice.

  2001cited by this paper
• The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

  2001cited by this paper
• Leptin-regulated endocannabinoids are involved in maintaining food intake

  2001cited by this paper
• Treatment of obesity: need to focus on high risk abdominally obese patients

  2001cited by this paper
• SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset.

  1998cited by this paper
• In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum

  1998cited by this paper
• Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors

  1997cited by this paper
• The beneficial effects of modest weight loss on cardiovascular risk factors.

  1997cited by this paper
• Molecular characterization of a peripheral receptor for cannabinoids

  1993cited by this paper
• Beneficial health effects of modest weight loss.

  1992cited by this paper
• Beneficial health effects of modest weight loss

  1992cited by this paper
• Laboratory Test Handbook

  1990cited by this paper
• Structure of a cannabinoid receptor and functional expression of the cloned cDNA

  1990cited by this paper
• High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.

  1989cited by this paper
• The Hospital Anxiety and Depression Scale.

  1987cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper
• The Hospital Anxiety and Depression Scale

  1983cited by this paper

• Discrete Choice Experiment (DCE) as a Tool to Elicit Patient Preferences in a Complex Benefit–Risk Evaluation: A Case Study

  2026cites this paper
• Next-generation therapeutics for diabetic kidney disease.

  2026cites this paper
• Psychopharmacotherapy in eating disorders: a systematic analysis.

  2025cites this paper
• Cannabinoid type-1 receptors in CaMKII neurons drive impulsivity in pathological eating behavior

  2025cites this paper
• Anti-Dyslipidemic, Anti-Hypertensive, and Glycemic Control Effects of Akkermansia Muciniphila: Lesser-Known Benefits in Metabolic Syndrome – A Narrative Review

  2025cites this paper
• Endocannabinoid and AGE Interactions in Prediabetes: The Role of Mediterranean Diet Adherence

  2025cites this paper
• Cannabis Medicine 2.0: Nanotechnology-Based Delivery Systems for Synthetic and Chemically Modified Cannabinoids for Enhanced Therapeutic Performance

  2025cites this paper
• Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial.

  2025cites this paper
• The Endocannabinoid System: Implications in Gastrointestinal Physiology and Pathology

  2025cites this paper
• State of the Art Review: Thiazide diuretics exploit the endocannabinoid system via NAPE-PLD.

  2025cites this paper
• Synthesis and Pharmacological Characterization of Novel Peripheral Cannabinoid-1 Receptor Blockers Based on a Tricyclic Scaffold

  2025cites this paper
• Feasibility and Tolerability of Nabilone for the Treatment of Obesity: A Randomized Controlled Pilot Trial

  2025cites this paper
• Chemical Probes for Investigating the Endocannabinoid System.

  2025cites this paper
• Circulating endocannabinoids and brain anatomy: unraveling the weight loss connection through lifestyle and surgery approaches

  2025cites this paper
• Cannabinoids Block Fat-induced Incretin Release via CB1-dependent and CB1-independent Pathways in Intestinal Epithelium

  2024cites this paper
• The circulating and central endocannabinoid system in obesity and weight loss

  2024influential citation
• Bibliometric Analysis of Cannabis sativa Research: Trends, Challenges, and Future Directions

  2024cites this paper
• The endocannabinoid system in appetite regulation and treatment of obesity

  2024cites this paper
• Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile

  2024cites this paper
• Structural mechanism of CB1R binding to peripheral and biased inverse agonists

  2024cites this paper
• New peripherally-restricted CB1 receptor antagonists, PMG-505-010 and -013 ameliorate obesity-associated NAFLD and fibrosis.

  2024cites this paper
• Requiem for Rimonabant: Therapeutic Potential for Cannabinoid CB1 Receptor Antagonists after the Fall

  2023cites this paper
• Role of Cannabinoid Signaling in Cardiovascular Function and Ischemic Injury

  2023cites this paper
• Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity

  2023cites this paper
• The association of circulating endocannabinoids with cancer cachexia: A cross-sectional study.

  2023cites this paper
• Pharmacohistory of Cannabis Use—A New Possibility in Future Drug Development for Gastrointestinal Diseases

  2023cites this paper
• Cannabis Sativa in Phytotherapy: Reappraisal of Therapeutic Potential and Regulatory Aspects.

  2023cites this paper
• Association of anandamide and 2-arachidonoylglycerol concentrations with clinical features and body mass index in eating disorders and obesity

  2023cites this paper
• Novel cannabinoid receptor 1 inverse agonist CRB‐913 enhances efficacy of tirzepatide, semaglutide, and liraglutidein the diet‐induced obesity mouse model

  2023cites this paper
• Effect of cannabis and subproducts on anthropometric measures: a systematic review and meta-analysis

  2023cites this paper
• Inhibitors of cannabinoid receptor 1 suppress the cellular entry of Lujo virus

  2023cites this paper
• Symposium on Biological Causes and Coping Strategies

  2023cites this paper
• Therapeutics in Metabolic Diseases.

  2023cites this paper
• Down the Rabbit Hole: Reviewing the Evidence for Primary Prevention of Cardiovascular Disease in People with Obesity.

  2023cites this paper
• Discovery of the First Raptor (Regulatory-Associated Protein of mTOR) Inhibitor as a New Type of Antiadipogenic Agent.

  2023cites this paper
• Recent Advances in Pyrazole-based Protein Kinase Inhibitors as Emerging Therapeutic Targets.

  2023cites this paper
• Consideration of sex and gender differences in addiction medication response

  2022cites this paper
• Hepatic targeting of the centrally active cannabinoid 1 receptor (CB1R) blocker rimonabant via PLGA nanoparticles for treating fatty liver disease and diabetes

  2022cites this paper
• Organocatalytic atroposelective construction of axially chiral N, N- and N, S-1,2-azoles through novel ring formation approach

  2022cites this paper
• Targeting appetite and satiety in diabetes and obesity, via G protein-coupled receptors.

  2022cites this paper
• Weight loss outcomes are not compromised in bariatric patients using cannabis

  2022cites this paper
• Anandamide is associated with waist-to-hip ratio but not with body mass index in women with polycystic ovary syndrome.

  2022cites this paper
• Pep19 Has a Positive Effect on Insulin Sensitivity and Ameliorates Both Hepatic and Adipose Tissue Phenotype of Diet-Induced Obese Mice

  2022cites this paper
• Licorice Extract Supplementation Affects Antioxidant Activity, Growth-Related Genes, Lipid Metabolism, and Immune Markers in Broiler Chickens

  2022cites this paper
• Circulating endocannabinoid levels in pregnant women with gestational diabetes mellitus: a case–control study

  2022cites this paper
• Les approches thérapeutiques non invasives de l’obésité : hier, aujourd’hui et demain

  2022cites this paper
• Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities.

  2022cites this paper
• Medical treatment of weight loss in children and adolescents with obesity.

  2022cites this paper
• Blockade of CB1 or Activation of CB2 Cannabinoid Receptors Is Differentially Efficacious in the Treatment of the Early Pathological Events in Streptozotocin-Induced Diabetic Rats

  2022cites this paper
• Effects of the cannabinoid CB1-receptor neutral antagonist AM4113 and antagonist/inverse agonist rimonabant on fentanyl discrimination in male rats.

  2022cites this paper
• Chemical Synthesis, Pharmacokinetic Properties and Biological Effects of JM-00266, a Putative Non-Brain Penetrant Cannabinoid Receptor 1 Inverse Agonist

  2022cites this paper
• CB1 Ligand AM251 Induces Weight Loss and Fat Reduction in Addition to Increased Systemic Inflammation in Diet-Induced Obesity

  2022cites this paper
• Medikamentöse Therapie der Adipositas

  2021cites this paper
• The Neurobiology of Binge-Eating Disorder Differs from Obesity: Implications for Differential Therapeutics

  2021cites this paper
• Endogenous cannabinoids are required for MC4R-mediated control of energy homeostasis

  2021cites this paper
• Metabolic and inflammatory functions of cannabinoid receptor type 1 are differentially modulated by adiponectin

  2021cites this paper
• Cannabis sativa as a Treatment for Obesity: From Anti-Inflammatory Indirect Support to a Promising Metabolic Re-Establishment Target

  2021cites this paper
• Rimonabant potentiates the antifungal activity of amphotericin B by increasing cellular oxidative stress and cell membrane permeability.

  2021cites this paper
• Extrapolation from Clinical Trial to Practice: Current Pharmacotherapy on Obesity

  2021cites this paper
• Direct Stimulatory Effects of the CB2 Ligand JTE 907 in Human and Mouse Islets

  2021cites this paper
• In Vivo Receptor Visualization and Evaluation of Receptor Occupancy with Positron Emission Tomography.

  2021cites this paper
• Cannabinoid CB1 receptor in dorsal telencephalic glutamatergic neurons drives overconsumption of palatable food and obesity

  2021cites this paper
• Functional Selectivity of a Biased Cannabinoid-1 Receptor (CB1R) Antagonist

  2021cites this paper
• Cannabis and Cannabis Edibles: A Review.

  2021cites this paper
• Anti-obesity drug discovery: advances and challenges

  2021cites this paper
• The endocannabinoid system in the adipose organ

  2021cites this paper
• Long-term effects of weight-reducing drugs in people with hypertension.

  2021cites this paper
• Beneficial Effects of Akkermansia muciniphila Are Not Associated with Major Changes in the Circulating Endocannabinoidome but Linked to Higher Mono-Palmitoyl-Glycerol Levels as New PPARα Agonists

  2021cites this paper
• Cannabinoids as anticancer and neuroprotective drugs: Structural insights and pharmacological interactions—A review

  2021cites this paper
• Pharmacological Selection of Cannabinoid Receptor Effectors: Signalling, Allosteric Modulation and Bias.

  2021cites this paper
• Modulatory role of the Endocannabinoidome in the pathophysiology of the gastrointestinal tract.

  2021cites this paper
• What Role Does the Endocannabinoid System Play in the Pathogenesis of Obesity?

  2021cites this paper
• Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox

  2021cites this paper
• Simultaneous Inhibition of Peripheral CB1R and iNOS Mitigates Obesity-Related Dyslipidemia Through Distinct Mechanisms

  2020cites this paper
• Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-TH1A and TRPV1 receptor mechanisms.

  2020cites this paper
• Naturally Occurring Cannabinoids and their Role in Modulation of Cardiovascular Health

  2020cites this paper
• Iodolopyrazolium Salts: Synthesis, Derivatizations, and Applications.

  2020cites this paper
• Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies.

  2020cites this paper
• Maternal transfer of environmentally relevant polybrominated diphenyl ethers (PBDEs) produces a diabetic phenotype and disrupts glucoregulatory hormones and hepatic endocannabinoids in adult mouse female offspring

  2020cites this paper
• Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs

  2020cites this paper
• Effects of a High-Protein Diet on Cardiometabolic Health, Vascular Function, and Endocannabinoids—A PREVIEW Study

  2020cites this paper
• Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol

  2020cites this paper
• Neurological Modulations of Sleep

  2020cites this paper
• Peptides from Natural or Rationally Designed Sources Can Be Used in Overweight, Obesity, and Type 2 Diabetes Therapies

  2020cites this paper
• Progress in Genetic Polymorphisms Related to Lipid Disturbances Induced by Atypical Antipsychotic Drugs

  2020cites this paper
• Interactions Between Alcohol and the Endocannabinoid System.

  2020influential citation
• Endocrine Manifestations of Alcohol and Other Drug Use Disorders

  2020cites this paper
• The Neurobiology of Binge-eating Disorder Compared with Obesity: Implications for Differential Therapeutics.

  2020cites this paper
• The cannabinoid ligands SR141716A and AM251 enhance human and mouse islet function via GPR55-independent signalling

  2020cites this paper
• The Effect Of CB1 Antagonism On Hepatic Oxidative/Nitrosative Stress And Inflammation In Nonalcoholic Fatty Liver Disease.

  2020cites this paper
• Evidence for the Endocannabinoid System as a Therapeutic Target in the Treatment of Cannabis Use Disorder

  2020cites this paper
• The therapeutic potential of second and third generation CB1R antagonists.

  2020cites this paper
• Clinical effect of catgut implantation at acupoints for the treatment of simple obesity

  2020cites this paper
• Biphasic Regulation of Mesenchymal Genes Controls Fate Switches During Hematopoietic Differentiation of Human Pluripotent Stem Cells

  2020cites this paper
• [Review Articles].

  2020cites this paper
• A combination of dietary fat intake and nicotine exposure enhances CB1 endocannabinoid receptor expression in hypothalamic nuclei in male mice.

  2020cites this paper
• Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide).

  2020cites this paper
• PET Imaging of the Endocannabinoid System

  2020cites this paper
• The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications

  2020cites this paper
• Circadian misalignment of the 24-hr profile of endocannabinoid 2-arachidonoylglycerol (2-AG) in obese adults.

  2020cites this paper